<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01365455</url>
  </required_header>
  <id_info>
    <org_study_id>CAIN457A2302</org_study_id>
    <secondary_id>2010-023512-13</secondary_id>
    <nct_id>NCT01365455</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Subcutaneous Secukinumab for Moderate to Severe Chronic Plaque-type Psoriasis for up to 1 Year</brief_title>
  <acronym>ERASURE</acronym>
  <official_title>A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability and Long-term Efficacy up to One Year in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the safety and efficacy of secukinumab compared to placebo in patients
      that have moderate to severe, chronic, plaque-type psoriasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved &gt;75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Who Achieved (Investigator's Global Assessment) IGA Score of 0 or 1</measure>
    <time_frame>12 weeks</time_frame>
    <description>The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1. IGA score of 0 or 1 as an indicator of efficacy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved a PASI (Psoriasis Area and Severity Index) Score of 90 or Better at Week 12</measure>
    <time_frame>12 weeks</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 90 was defined as participants who achievied ≥ 90% improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Maintained the Psoriasis Area and Severity Index (PASI) 75 Response at 52 Weeks of Treatment for Participants Who Were PASI 75 Responders at Week 12</measure>
    <time_frame>12 and 52 weeks</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Maintained the IGA Mod 2011 0 or 1 Response at 52 Weeks of Treatment for Participants Who Were IGA Mod 2011 0 or 1 Responders at Week 12</measure>
    <time_frame>12 and 52 weeks</time_frame>
    <description>The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Week 12 in Psoriasis Symptom Diary Items Itching, Pain and Scaling in AIN457 vs Placebo</measure>
    <time_frame>Week 12</time_frame>
    <description>The Psoriasis Symptom Diary©, a 16-item patient reported outcome (PRO) measure developed and validated in accordance with the FDA PRO Guidance (FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009), demonstrated favorable psychometric properties and usefulness for treatment efficacy evaluation alongside other measures of disease severity in clinical trials for chronic plaque psoriasis.Weekly averages will be derived for each of the 16 questions of the Psoriasis Diary up to Week 12. A weekly average is the sum of the scored item over the course of the study week divided by the number of days on which the item was completed and will be set to missing if four or more daily assessments were missing of the corresponding question. A reduction in score from baseline shows efficacy. Each question has a score of 0 (no symptoms) up to 10 (Severe symptoms)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response up to 12 Weeks Induction Period</measure>
    <time_frame>Week 1,2,3,4,8,12,</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (max). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response Maintenance Period After Week 12 to Week 52</measure>
    <time_frame>Week 13,14,15,16,20,24,28,32,36,40,44,48,52</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (max). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in PASI Scores up to Week 12 - Induction Period</measure>
    <time_frame>Baseline, Week 1,2,3,4,8,12,</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in PASI Scores Maintenance Period After Week 12 to Week 52</measure>
    <time_frame>Week 13,14,15,16,20,24,28,32,36,40,44,48,52</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each IGA Mod 2011 Score Category up to Week 12 - Induction Period</measure>
    <time_frame>Baseline, Week 1,2,3,4,8,12,</time_frame>
    <description>The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Each IGA Mod 2011 Score Category Maintenance Period After Week 12 to Week 52</measure>
    <time_frame>Week 13,14,15,16,20,24,28,32,36,40,44,48,52</time_frame>
    <description>The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to PASI 75 Response up to 12 Weeks</measure>
    <time_frame>Week 12</time_frame>
    <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (max). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 75 was defined as participants achieving ≥ 75% improvement from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) Health State Assessment (From 0 to 100) Induction Period</measure>
    <time_frame>Baseline, Week 4,8, 12</time_frame>
    <description>The EQ-5D is an instrument used to assess a participant's health status. The instrument includes a descriptive profile and a visual analog scale (VAS). The descriptive profile includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 3 response levels: no problems, some problems and severe problems. The VAS is a vertical scale that assesses the health status from 0 (worst possible health state) to 100 (best possible health state). This outcome measures the percent change in VAS score. Positive mean percent changes indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Percent Change From Baseline in EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) Health State Assessment (From 0 to 100) Maintenance Period</measure>
    <time_frame>Week 12, 24, 36, 52</time_frame>
    <description>The EQ-5D is an instrument used to assess a participant's health status. The instrument includes a descriptive profile and a visual analog scale (VAS). The descriptive profile includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 3 response levels: no problems, some problems and severe problems. The VAS is a vertical scale that assesses the health status from 0 (worst possible health state) to 100 (best possible health state). This outcome measures the percent change in VAS score. Positive mean percent changes indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Changes in the Dermatology Life Quality Index (DLQI) During Induction Period</measure>
    <time_frame>Baseline, Week 4, 8 &amp; 12</time_frame>
    <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Changes in the Dermatology Life Quality Index (DLQI) During Maintenance Period</measure>
    <time_frame>Week 12,24, 36 &amp; 52</time_frame>
    <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) of 0 or 1 During Induction Period</measure>
    <time_frame>Week 4, 8, 12</time_frame>
    <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) of 0 or 1 During Maintenance Period</measure>
    <time_frame>Week 12,24,36, &amp; 52</time_frame>
    <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving PASI 75, PASI 90 and IGA Mod 2011 0 or 1 Response at Week 12 by Previous Exposure to Biologic Systemic Therapy or Anti-TNF-α Therapy and Failed to Respond to a Previous Biologic or Anti-TNF-α Therapy Psoriasis Therapy</measure>
    <time_frame>Week 12</time_frame>
    <description>PASI is an assessment of lesion severity &amp; affected area into a single score:0(no disease)to 72(max. disease).Body is divided into 4 areas for scoring(head,arms,trunk,legs)each area is scored separately &amp; then added for final PASI.For each area, % of skin involved is estimated:0(0%)to 6(90-100%)&amp; severity is estimated by clinical signs, erythema,induration &amp; desquamation;scale 0(none) to 4(max). Final PASI=sum of severity parameters for each area* area score weight of section(head:0.1,arms:0.2 body:0.3 legs:0.4).PASI 75, 90 is patients achieving≥75%or90% improvement from baseline.The IGA mod 2011 scale is static, exclusively to the patients disease at assessment,&amp; not with any of the patient's previous disease states at other visits.The scores are:0=clear,1=almost clear,2= mild,3=moderate&amp;4=severe.Response variables PASI 75,90, IGA mod 2011 0 or 1 response at wk 12 was scored versus previous psoriasis systemic therapy &amp; response to previous biologic systemic therapy by treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Developed Anti-secukinumab Antibodies</measure>
    <time_frame>Week 12</time_frame>
    <description>The development of anti-secunimubab anti-bodies would decrease a participant's ability to respond to secukinumab treatment.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">738</enrollment>
  <condition>Moderate to Severe Plaque-type Psoriasis</condition>
  <arm_group>
    <arm_group_label>AIN457 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 150mg from Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AIN457 300mg from Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>secukinumab 150 mg</intervention_name>
    <description>secukinumab (AIN457) 150mg or 300mg subcutaneous</description>
    <arm_group_label>AIN457 150 mg</arm_group_label>
    <arm_group_label>AIN457 300 mg</arm_group_label>
    <arm_group_label>AIN457 150mg from Placebo</arm_group_label>
    <arm_group_label>AIN457 300mg from Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo to secukinumab 150 mg</intervention_name>
    <description>Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous</description>
    <arm_group_label>AIN457 150 mg</arm_group_label>
    <arm_group_label>AIN457 300 mg</arm_group_label>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_label>AIN457 150mg from Placebo</arm_group_label>
    <arm_group_label>AIN457 300mg from Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Moderate and severe plaque-type psoriasis diagnosed for at least 6 months.

          -  Severity of psoriasis disease meeting all of the following three criteria:

          -  Psoriasis Area and Severity Index (PASI) score of 12 or greater,

          -  Investigator's Global Assessment (IGA) score of 3 or greater,

          -  Total body surface area (BSA) affected of 10% or greater.

          -  Inadequate control by prior use of topical treatment, phototherapy and/or systemic
             therapy.

        Exclusion criteria:

          -  Current forms of psoriasis other than chronic plaque-type psoriasis (for example,
             pustular, erythrodermic, guttate).

          -  Current drug-induced psoriasis.

          -  Previous use of secukinumab or any drug that targets IL-17 or IL-17 receptor.

          -  Significant medical problems such as uncontrolled hypertension, congestive heart
             failure or a condition that significantly immunocompromises the subject.

          -  Hematological abnormalities.

          -  History of an ongoing, chronic or recurrent infectious disease, or evidence of
             untreated tuberculosis.

          -  History of lymphoproliferative disease or history of malignancy of any organ system
             within the past 5 years.

          -  Pregnant or nursing (lactating) women.

          -  Subjects not willing to limit UV light exposure during the study Other
             protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Novartis Pharmceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <zip>92056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80915</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Snellville</city>
        <state>Georgia</state>
        <zip>30078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <zip>47713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40291</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oregon City</city>
        <state>Oregon</state>
        <zip>97045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bryan</city>
        <state>Texas</state>
        <zip>77802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246-1613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1122AAF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1181ACH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1425AWC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mendoza</city>
        <zip>M5502EZA</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Peterborough</city>
        <state>Ontario</state>
        <zip>K9J 5K2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <zip>N2J 1C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3H 1V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <state>Atlantico</state>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Barranquilla</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bucaramanga</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10617</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13419</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tartu</city>
        <zip>51014</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kopavogur</city>
        <zip>IS-201</zip>
        <country>Iceland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Afula</city>
        <zip>18101</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Petach Tikva</city>
        <zip>49100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya-city</city>
        <state>Aichi</state>
        <zip>467-8602</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>814-0180</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <zip>830-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maebashi-city</city>
        <state>Gunma</state>
        <zip>371-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Asahikawa-city</city>
        <state>Hokkaido</state>
        <zip>078-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo-city</city>
        <state>Hokkaido</state>
        <zip>060-0063</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kobe-City</city>
        <state>Hyogo</state>
        <zip>654-0155</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Inashiki-gun</city>
        <state>Ibaraki</state>
        <zip>300-0395</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Isehara-city</city>
        <state>Kanagawa</state>
        <zip>259-1193</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawasaki-city</city>
        <state>Kanagawa</state>
        <zip>213-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sagamihara-city</city>
        <state>Kanagawa</state>
        <zip>228-8522</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiyoda-ku</city>
        <state>Tokyo</state>
        <zip>102-8798</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minato-ku</city>
        <state>Tokyo</state>
        <zip>105-8471</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinagawa-ku</city>
        <state>Tokyo</state>
        <zip>141-8625</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-0023</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5404</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>1012</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Riga</city>
        <zip>LV-1001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ventspils</city>
        <zip>LV-3601</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>92304</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-07195</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>06780</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>México</city>
        <state>Distrito Federal</state>
        <zip>14050</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Zapopan</city>
        <state>Jalisco</state>
        <zip>45190</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hsin Chu</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Canada</country>
    <country>Colombia</country>
    <country>Estonia</country>
    <country>Iceland</country>
    <country>Israel</country>
    <country>Japan</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Mexico</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Panama</country>
    <country>Peru</country>
    <country>Russian Federation</country>
  </removed_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2011</study_first_submitted>
  <study_first_submitted_qc>June 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2011</study_first_posted>
  <results_first_submitted>February 16, 2015</results_first_submitted>
  <results_first_submitted_qc>May 7, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 29, 2015</results_first_posted>
  <last_update_submitted>January 19, 2016</last_update_submitted>
  <last_update_submitted_qc>January 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>plaque</keyword>
  <keyword>plaque-type psoriasis</keyword>
  <keyword>IL-17 blocker</keyword>
  <keyword>subcutaneous</keyword>
  <keyword>psoriatic arthritis</keyword>
  <keyword>injection</keyword>
  <keyword>AIN457</keyword>
  <keyword>AIN457A</keyword>
  <keyword>secukinumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Not all patients that completed Maintenance Period continued in the follow-up Period. Many patients from Maintence rolled into CAIN457A2302E1 study</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>AIN457 150 mg</title>
          <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
        </group>
        <group group_id="P2">
          <title>AIN457 300 mg</title>
          <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
        </group>
        <group group_id="P4">
          <title>AIN457 150mg From Placebo</title>
          <description>Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
        </group>
        <group group_id="P5">
          <title>AIN457 300mg From Placebo</title>
          <description>Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Induction Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
                <participants group_id="P2" count="245"/>
                <participants group_id="P3" count="248"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="238"/>
                <participants group_id="P3" count="232"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Maintenance Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="230"/>
                <participants group_id="P2" count="238"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="109"/>
                <participants group_id="P5" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="201"/>
                <participants group_id="P2" count="215"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="100"/>
                <participants group_id="P5" count="92"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="9"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with study treatment</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject/guardian decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Follow-up Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="47"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AIN457 150 mg</title>
          <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
        </group>
        <group group_id="B2">
          <title>AIN457 300 mg</title>
          <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="245"/>
            <count group_id="B2" value="245"/>
            <count group_id="B3" value="248"/>
            <count group_id="B4" value="738"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.9" spread="13.33"/>
                    <measurement group_id="B2" value="44.9" spread="13.46"/>
                    <measurement group_id="B3" value="45.4" spread="12.63"/>
                    <measurement group_id="B4" value="45.1" spread="13.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="77"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="172"/>
                    <measurement group_id="B4" value="509"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved &gt;75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks</title>
        <description>A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved &gt;75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks</title>
          <description>A 75% reduction in the Psoriasis Area and Severity Index (PASI) score (PASI 75) is the current benchmark of primary endpoints for most clinical trials of psoriasis. PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6"/>
                    <measurement group_id="O2" value="81.6"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Achieved (Investigator's Global Assessment) IGA Score of 0 or 1</title>
        <description>The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1. IGA score of 0 or 1 as an indicator of efficacy.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved (Investigator's Global Assessment) IGA Score of 0 or 1</title>
          <description>The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1. IGA score of 0 or 1 as an indicator of efficacy.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="244"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2"/>
                    <measurement group_id="O2" value="65.3"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved a PASI (Psoriasis Area and Severity Index) Score of 90 or Better at Week 12</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 90 was defined as participants who achievied ≥ 90% improvement from baseline.</description>
        <time_frame>12 weeks</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved a PASI (Psoriasis Area and Severity Index) Score of 90 or Better at Week 12</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 90 was defined as participants who achievied ≥ 90% improvement from baseline.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="243"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1"/>
                    <measurement group_id="O2" value="59.2"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Maintained the Psoriasis Area and Severity Index (PASI) 75 Response at 52 Weeks of Treatment for Participants Who Were PASI 75 Responders at Week 12</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</description>
        <time_frame>12 and 52 weeks</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Maintained the Psoriasis Area and Severity Index (PASI) 75 Response at 52 Weeks of Treatment for Participants Who Were PASI 75 Responders at Week 12</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4).</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PASI 75 response at Week 12 (n=243, 245, 246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174"/>
                    <measurement group_id="O2" value="200"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintained PASI 75 response at Wk 52(n=174,200,11)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="161"/>
                    <measurement group_id="O3" value="NA">After W12: Efficacy was not focus for PBO group and therefore no data was provided at Week 52</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Maintained the IGA Mod 2011 0 or 1 Response at 52 Weeks of Treatment for Participants Who Were IGA Mod 2011 0 or 1 Responders at Week 12</title>
        <description>The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.</description>
        <time_frame>12 and 52 weeks</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Maintained the IGA Mod 2011 0 or 1 Response at 52 Weeks of Treatment for Participants Who Were IGA Mod 2011 0 or 1 Responders at Week 12</title>
          <description>The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe. Treatment success was defined as achievement of IGA mod 2001 score of 0 or 1.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>number of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IGA mod2011 0or1 response at Wk 12(n=244,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="125"/>
                    <measurement group_id="O2" value="160"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maintained IGAmod2011 0or1 resp atWk52 n=125,160,6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="NA">After W12: Efficacy was not focus for PBO group and therefore no data was provided at Week 52</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Week 12 in Psoriasis Symptom Diary Items Itching, Pain and Scaling in AIN457 vs Placebo</title>
        <description>The Psoriasis Symptom Diary©, a 16-item patient reported outcome (PRO) measure developed and validated in accordance with the FDA PRO Guidance (FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009), demonstrated favorable psychometric properties and usefulness for treatment efficacy evaluation alongside other measures of disease severity in clinical trials for chronic plaque psoriasis.Weekly averages will be derived for each of the 16 questions of the Psoriasis Diary up to Week 12. A weekly average is the sum of the scored item over the course of the study week divided by the number of days on which the item was completed and will be set to missing if four or more daily assessments were missing of the corresponding question. A reduction in score from baseline shows efficacy. Each question has a score of 0 (no symptoms) up to 10 (Severe symptoms)</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Psoriasis Symptom Diary Items Itching, Pain and Scaling in AIN457 vs Placebo</title>
          <description>The Psoriasis Symptom Diary©, a 16-item patient reported outcome (PRO) measure developed and validated in accordance with the FDA PRO Guidance (FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, 2009), demonstrated favorable psychometric properties and usefulness for treatment efficacy evaluation alongside other measures of disease severity in clinical trials for chronic plaque psoriasis.Weekly averages will be derived for each of the 16 questions of the Psoriasis Diary up to Week 12. A weekly average is the sum of the scored item over the course of the study week divided by the number of days on which the item was completed and will be set to missing if four or more daily assessments were missing of the corresponding question. A reduction in score from baseline shows efficacy. Each question has a score of 0 (no symptoms) up to 10 (Severe symptoms)</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Scores on a Scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>itching (n=86,79,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.86" spread="0.299"/>
                    <measurement group_id="O2" value="-545" spread="0.276"/>
                    <measurement group_id="O3" value="-0.22" spread="0.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>pain (n=86,79,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.92" spread="0.337"/>
                    <measurement group_id="O2" value="-4.59" spread="0.322"/>
                    <measurement group_id="O3" value="0.06" spread="0.246"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>scaling (n=86,79,84)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.74" spread="0.307"/>
                    <measurement group_id="O2" value="-5.49" spread="0.289"/>
                    <measurement group_id="O3" value="-0.11" spread="0.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response up to 12 Weeks Induction Period</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (max). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
        <time_frame>Week 1,2,3,4,8,12,</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response up to 12 Weeks Induction Period</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (max). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 IGA 0/1 (n=244,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 PASI 75 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 PASI 50 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 PASI 90 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 PASI 100 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 IGA 0/1 n=244,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 PASI 75 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="4.1"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 PASI 50 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.5"/>
                    <measurement group_id="O2" value="28.2"/>
                    <measurement group_id="O3" value="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 PASI 90 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 PASI 100 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 IGA 0/1( n=244,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="11.0"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 PASI 75 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="15.5"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 PASI 50 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                    <measurement group_id="O2" value="53.1"/>
                    <measurement group_id="O3" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 PASI 90 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="2.9"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 PASI 100 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 IGA 0/1( n=244,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.2"/>
                    <measurement group_id="O2" value="26.1"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 PASI 75 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="38.0"/>
                    <measurement group_id="O3" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 PASI 50 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.0"/>
                    <measurement group_id="O2" value="74.7"/>
                    <measurement group_id="O3" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 PASI 90 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8"/>
                    <measurement group_id="O2" value="10.6"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 PASI 100 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 IGA 0/1( n=244,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2"/>
                    <measurement group_id="O2" value="60.0"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 PASI 75 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.7"/>
                    <measurement group_id="O2" value="76.7"/>
                    <measurement group_id="O3" value="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 PASI 50 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.5"/>
                    <measurement group_id="O2" value="92.2"/>
                    <measurement group_id="O3" value="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 PASI 90 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.8"/>
                    <measurement group_id="O2" value="47.8"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 PASI 100 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 IGA 0/1( n=244,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2"/>
                    <measurement group_id="O2" value="65.3"/>
                    <measurement group_id="O3" value="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 PASI 75 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6"/>
                    <measurement group_id="O2" value="81.6"/>
                    <measurement group_id="O3" value="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 PASI 50 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5"/>
                    <measurement group_id="O2" value="90.6"/>
                    <measurement group_id="O3" value="8.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 PASI 90 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1"/>
                    <measurement group_id="O2" value="59.2"/>
                    <measurement group_id="O3" value="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 PASI 100 (n=243,245,246)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8"/>
                    <measurement group_id="O2" value="28.6"/>
                    <measurement group_id="O3" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response Maintenance Period After Week 12 to Week 52</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (max). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
        <time_frame>Week 13,14,15,16,20,24,28,32,36,40,44,48,52</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
          <group group_id="O4">
            <title>AIN457 150mg From Placebo</title>
            <description>Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
          <group group_id="O5">
            <title>AIN457 300mg From Placebo</title>
            <description>Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PASI 50/75/90/100 Response or IGA 0 or 1 Response Maintenance Period After Week 12 to Week 52</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (max). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 50, 75, 90 and 100 were defined as participants achieving ≥ 50%, 75%, 90% or 100% improvement from baseline. The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate and 4 = severe.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="108"/>
                <count group_id="O5" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 13 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.6"/>
                    <measurement group_id="O2" value="66.9"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="0.9"/>
                    <measurement group_id="O5" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.8"/>
                    <measurement group_id="O2" value="79.6"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 PASI 50 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.5"/>
                    <measurement group_id="O2" value="87.3"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="12.0"/>
                    <measurement group_id="O5" value="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9"/>
                    <measurement group_id="O2" value="60.8"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="0.9"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0"/>
                    <measurement group_id="O2" value="30.2"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.3"/>
                    <measurement group_id="O2" value="74.7"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="4.6"/>
                    <measurement group_id="O5" value="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0"/>
                    <measurement group_id="O2" value="86.1"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="7.4"/>
                    <measurement group_id="O5" value="14.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 PASI 50 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.1"/>
                    <measurement group_id="O2" value="91.4"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="34.3"/>
                    <measurement group_id="O5" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6"/>
                    <measurement group_id="O2" value="68.2"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="0.9"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.5"/>
                    <measurement group_id="O2" value="35.5"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.4"/>
                    <measurement group_id="O2" value="75.1"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="13.0"/>
                    <measurement group_id="O5" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.3"/>
                    <measurement group_id="O2" value="87.8"/>
                    <measurement group_id="O3" value="55.6"/>
                    <measurement group_id="O4" value="13.9"/>
                    <measurement group_id="O5" value="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 PASI 50 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4"/>
                    <measurement group_id="O2" value="92.2"/>
                    <measurement group_id="O3" value="72.2"/>
                    <measurement group_id="O4" value="55.6"/>
                    <measurement group_id="O5" value="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.0"/>
                    <measurement group_id="O2" value="68.6"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8"/>
                    <measurement group_id="O2" value="40.8"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2"/>
                    <measurement group_id="O2" value="73.5"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="25.9"/>
                    <measurement group_id="O5" value="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4"/>
                    <measurement group_id="O2" value="86.1"/>
                    <measurement group_id="O3" value="61.1"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 PASI 50 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.2"/>
                    <measurement group_id="O2" value="91.4"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="68.5"/>
                    <measurement group_id="O5" value="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.5"/>
                    <measurement group_id="O2" value="69.8"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="10.2"/>
                    <measurement group_id="O5" value="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0"/>
                    <measurement group_id="O2" value="41.6"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="0.9"/>
                    <measurement group_id="O5" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.4"/>
                    <measurement group_id="O2" value="74.7"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="51.9"/>
                    <measurement group_id="O5" value="55.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.0"/>
                    <measurement group_id="O2" value="86.9"/>
                    <measurement group_id="O3" value="72.2"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 PASI 50 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.3"/>
                    <measurement group_id="O2" value="92.7"/>
                    <measurement group_id="O3" value="88.9"/>
                    <measurement group_id="O4" value="87.0"/>
                    <measurement group_id="O5" value="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="69.8"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="38.0"/>
                    <measurement group_id="O5" value="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="43.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="5.6"/>
                    <measurement group_id="O5" value="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.2"/>
                    <measurement group_id="O2" value="71.4"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="57.4"/>
                    <measurement group_id="O5" value="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.8"/>
                    <measurement group_id="O2" value="85.7"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="76.9"/>
                    <measurement group_id="O5" value="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 PASI 50 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8"/>
                    <measurement group_id="O2" value="91.0"/>
                    <measurement group_id="O3" value="88.9"/>
                    <measurement group_id="O4" value="91.7"/>
                    <measurement group_id="O5" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7"/>
                    <measurement group_id="O2" value="70.2"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="50.9"/>
                    <measurement group_id="O5" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9"/>
                    <measurement group_id="O2" value="42.4"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.7"/>
                    <measurement group_id="O2" value="68.6"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="61.1"/>
                    <measurement group_id="O5" value="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4"/>
                    <measurement group_id="O2" value="82.9"/>
                    <measurement group_id="O3" value="72.2"/>
                    <measurement group_id="O4" value="74.1"/>
                    <measurement group_id="O5" value="87.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 PASI 50 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4"/>
                    <measurement group_id="O2" value="90.2"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="91.7"/>
                    <measurement group_id="O5" value="93.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.1"/>
                    <measurement group_id="O2" value="68.6"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="71.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3"/>
                    <measurement group_id="O2" value="43.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="24.1"/>
                    <measurement group_id="O5" value="33.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8"/>
                    <measurement group_id="O2" value="68.2"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="57.4"/>
                    <measurement group_id="O5" value="76.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0"/>
                    <measurement group_id="O2" value="81.2"/>
                    <measurement group_id="O3" value="61.1"/>
                    <measurement group_id="O4" value="75.0"/>
                    <measurement group_id="O5" value="89.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 PASI 50 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.4"/>
                    <measurement group_id="O2" value="88.6"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="88.9"/>
                    <measurement group_id="O5" value="94.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.1"/>
                    <measurement group_id="O2" value="68.2"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="50.9"/>
                    <measurement group_id="O5" value="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="43.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="22.2"/>
                    <measurement group_id="O5" value="39.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.0"/>
                    <measurement group_id="O2" value="66.9"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="60.2"/>
                    <measurement group_id="O5" value="70.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.5"/>
                    <measurement group_id="O2" value="79.2"/>
                    <measurement group_id="O3" value="61.1"/>
                    <measurement group_id="O4" value="73.1"/>
                    <measurement group_id="O5" value="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 PASI 50 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.2"/>
                    <measurement group_id="O2" value="86.9"/>
                    <measurement group_id="O3" value="88.9"/>
                    <measurement group_id="O4" value="88.9"/>
                    <measurement group_id="O5" value="89.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4"/>
                    <measurement group_id="O2" value="67.3"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="52.8"/>
                    <measurement group_id="O5" value="64.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="42.4"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="25.0"/>
                    <measurement group_id="O5" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.1"/>
                    <measurement group_id="O2" value="64.9"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="57.4"/>
                    <measurement group_id="O5" value="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.4"/>
                    <measurement group_id="O2" value="76.7"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="69.4"/>
                    <measurement group_id="O5" value="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 PASI 50 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.6"/>
                    <measurement group_id="O2" value="84.9"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="88.0"/>
                    <measurement group_id="O5" value="88.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0"/>
                    <measurement group_id="O2" value="64.9"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="50.9"/>
                    <measurement group_id="O5" value="65.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0"/>
                    <measurement group_id="O2" value="40.8"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="24.1"/>
                    <measurement group_id="O5" value="42.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.3"/>
                    <measurement group_id="O2" value="60.4"/>
                    <measurement group_id="O3" value="44.4"/>
                    <measurement group_id="O4" value="57.4"/>
                    <measurement group_id="O5" value="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.4"/>
                    <measurement group_id="O2" value="79.2"/>
                    <measurement group_id="O3" value="61.1"/>
                    <measurement group_id="O4" value="68.5"/>
                    <measurement group_id="O5" value="79.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 PASI 50 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4"/>
                    <measurement group_id="O2" value="84.5"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="89.8"/>
                    <measurement group_id="O5" value="89.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8"/>
                    <measurement group_id="O2" value="61.2"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="47.2"/>
                    <measurement group_id="O5" value="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.8"/>
                    <measurement group_id="O2" value="37.1"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="23.1"/>
                    <measurement group_id="O5" value="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4"/>
                    <measurement group_id="O2" value="62.9"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="50.0"/>
                    <measurement group_id="O5" value="69.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.1"/>
                    <measurement group_id="O2" value="77.6"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="68.5"/>
                    <measurement group_id="O5" value="76.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 PASI 50 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.4"/>
                    <measurement group_id="O2" value="84.9"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="86.1"/>
                    <measurement group_id="O5" value="83.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5"/>
                    <measurement group_id="O2" value="63.7"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="45.4"/>
                    <measurement group_id="O5" value="63.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.2"/>
                    <measurement group_id="O2" value="40.4"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="20.4"/>
                    <measurement group_id="O5" value="37.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 IGA 0/1 (n=244,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.4"/>
                    <measurement group_id="O2" value="87.3"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="76.9"/>
                    <measurement group_id="O5" value="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 PASI 75 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.8"/>
                    <measurement group_id="O2" value="94.3"/>
                    <measurement group_id="O3" value="66.7"/>
                    <measurement group_id="O4" value="88.0"/>
                    <measurement group_id="O5" value="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 PASI 50(n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.8"/>
                    <measurement group_id="O2" value="95.9"/>
                    <measurement group_id="O3" value="83.3"/>
                    <measurement group_id="O4" value="96.3"/>
                    <measurement group_id="O5" value="81.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 PASI 90 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.3"/>
                    <measurement group_id="O2" value="84.5"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="66.7"/>
                    <measurement group_id="O5" value="62.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 PASI 100 (n=243,245,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2"/>
                    <measurement group_id="O2" value="62.0"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="36.1"/>
                    <measurement group_id="O5" value="43.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in PASI Scores up to Week 12 - Induction Period</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.</description>
        <time_frame>Baseline, Week 1,2,3,4,8,12,</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in PASI Scores up to Week 12 - Induction Period</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=243,243,242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.08" spread="19.225"/>
                    <measurement group_id="O2" value="-17.50" spread="17.317"/>
                    <measurement group_id="O3" value="-3.70" spread="14.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=243,245,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-28.61" spread="21.982"/>
                    <measurement group_id="O2" value="-36.51" spread="21.850"/>
                    <measurement group_id="O3" value="-5.63" spread="23.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=243,245,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-42.79" spread="23.695"/>
                    <measurement group_id="O2" value="-51.59" spread="22.415"/>
                    <measurement group_id="O3" value="-8.62" spread="25.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=243,245,245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.73" spread="24.252"/>
                    <measurement group_id="O2" value="-64.61" spread="22.080"/>
                    <measurement group_id="O3" value="-8.89" spread="28.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=243,245,245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-76.35" spread="20.427"/>
                    <measurement group_id="O2" value="-82.98" spread="19.331"/>
                    <measurement group_id="O3" value="-8.15" spread="32.755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=243,245,245)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80.87" spread="20.512"/>
                    <measurement group_id="O2" value="-87.72" spread="17.729"/>
                    <measurement group_id="O3" value="-5.89" spread="36.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in PASI Scores Maintenance Period After Week 12 to Week 52</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.</description>
        <time_frame>Week 13,14,15,16,20,24,28,32,36,40,44,48,52</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
          <group group_id="O4">
            <title>AIN457 150mg From Placebo</title>
            <description>Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
          <group group_id="O5">
            <title>AIN457 300mg From Placebo</title>
            <description>Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in PASI Scores Maintenance Period After Week 12 to Week 52</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72(maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). A negative mean percentage change indicates improvement.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="108"/>
                <count group_id="O5" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 13 (n=243,245,18,102,96)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.12" spread="19.313"/>
                    <measurement group_id="O2" value="-89.55" spread="15.935"/>
                    <measurement group_id="O3" value="-63.10" spread="36.827"/>
                    <measurement group_id="O4" value="-21.03" spread="28.240"/>
                    <measurement group_id="O5" value="-21.66" spread="29.891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=243,245,18,107,102)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-84.47" spread="18.832"/>
                    <measurement group_id="O2" value="-90.83" spread="15.013"/>
                    <measurement group_id="O3" value="-68.74" spread="30.225"/>
                    <measurement group_id="O4" value="-39.20" spread="26.228"/>
                    <measurement group_id="O5" value="-41.97" spread="28.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=243,245,18,107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-84.67" spread="19.407"/>
                    <measurement group_id="O2" value="-91.40" spread="14.769"/>
                    <measurement group_id="O3" value="-67.15" spread="32.972"/>
                    <measurement group_id="O4" value="-51.78" spread="23.561"/>
                    <measurement group_id="O5" value="-57.77" spread="23.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=243,245,18,107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85.20" spread="19.213"/>
                    <measurement group_id="O2" value="-91.37" spread="15.367"/>
                    <measurement group_id="O3" value="-73.38" spread="28.051"/>
                    <measurement group_id="O4" value="-62.19" spread="23.591"/>
                    <measurement group_id="O5" value="-70.15" spread="20.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=243,245,18,107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85.75" spread="17.904"/>
                    <measurement group_id="O2" value="-90.86" spread="16.263"/>
                    <measurement group_id="O3" value="-80.57" spread="22.454"/>
                    <measurement group_id="O4" value="-77.75" spread="20.587"/>
                    <measurement group_id="O5" value="-84.53" spread="16.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=243,245,18,107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-85.46" spread="20.240"/>
                    <measurement group_id="O2" value="-90.83" spread="16.652"/>
                    <measurement group_id="O3" value="-78.06" spread="25.062"/>
                    <measurement group_id="O4" value="-83.19" spread="18.635"/>
                    <measurement group_id="O5" value="-89.20" spread="13.969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=243,245,18,107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-84.72" spread="20.417"/>
                    <measurement group_id="O2" value="-90.15" spread="17.600"/>
                    <measurement group_id="O3" value="-79.55" spread="23.943"/>
                    <measurement group_id="O4" value="-84.07" spread="19.819"/>
                    <measurement group_id="O5" value="-91.24" spread="11.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=243,245,18,107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.98" spread="21.887"/>
                    <measurement group_id="O2" value="-89.90" spread="17.775"/>
                    <measurement group_id="O3" value="-75.94" spread="25.879"/>
                    <measurement group_id="O4" value="-84.26" spread="20.622"/>
                    <measurement group_id="O5" value="-91.09" spread="13.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36(n=243,245,18,107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-81.87" spread="25.048"/>
                    <measurement group_id="O2" value="-90.04" spread="17.981"/>
                    <measurement group_id="O3" value="-78.37" spread="24.608"/>
                    <measurement group_id="O4" value="-83.68" spread="20.328"/>
                    <measurement group_id="O5" value="-89.97" spread="16.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40(n=243,245,18,107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-81.37" spread="25.395"/>
                    <measurement group_id="O2" value="-89.62" spread="17.385"/>
                    <measurement group_id="O3" value="-78.32" spread="24.770"/>
                    <measurement group_id="O4" value="-82.83" spread="20.762"/>
                    <measurement group_id="O5" value="-89.76" spread="17.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=243,245,18,107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-80.81" spread="25.651"/>
                    <measurement group_id="O2" value="-88.97" spread="17.804"/>
                    <measurement group_id="O3" value="-79.96" spread="22.354"/>
                    <measurement group_id="O4" value="-83.44" spread="18.277"/>
                    <measurement group_id="O5" value="-89.37" spread="17.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48(n=243,245,18,107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.78" spread="26.471"/>
                    <measurement group_id="O2" value="-89.35" spread="17.281"/>
                    <measurement group_id="O3" value="-79.54" spread="21.506"/>
                    <measurement group_id="O4" value="-83.40" spread="18.736"/>
                    <measurement group_id="O5" value="-88.44" spread="18.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=243,245,18,107,103)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-79.74" spread="26.524"/>
                    <measurement group_id="O2" value="-88.42" spread="19.132"/>
                    <measurement group_id="O3" value="-79.64" spread="22.169"/>
                    <measurement group_id="O4" value="-82.14" spread="18.554"/>
                    <measurement group_id="O5" value="-87.66" spread="20.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Each IGA Mod 2011 Score Category up to Week 12 - Induction Period</title>
        <description>The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.</description>
        <time_frame>Baseline, Week 1,2,3,4,8,12,</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Each IGA Mod 2011 Score Category up to Week 12 - Induction Period</title>
          <description>The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=244,243,243) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="19.225"/>
                    <measurement group_id="O2" value="0.0" spread="17.317"/>
                    <measurement group_id="O3" value="0.0" spread="14.756"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=244,243,243) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="21.982"/>
                    <measurement group_id="O2" value="0.0" spread="21.850"/>
                    <measurement group_id="O3" value="0.0" spread="23.616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=244,243,243) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="23.695"/>
                    <measurement group_id="O2" value="9.1" spread="22.415"/>
                    <measurement group_id="O3" value="4.1" spread="25.785"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=244,243,243) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" spread="24.252"/>
                    <measurement group_id="O2" value="68.7" spread="22.080"/>
                    <measurement group_id="O3" value="60.9" spread="28.165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=244,243,243) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="22.2"/>
                    <measurement group_id="O3" value="35.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=244,245,244) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=244,245,244) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="4.5"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=244,245,244) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.0"/>
                    <measurement group_id="O2" value="27.8"/>
                    <measurement group_id="O3" value="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=244,245,244) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.0"/>
                    <measurement group_id="O2" value="55.5"/>
                    <measurement group_id="O3" value="59.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=244,245,244) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.9"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="34.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=244,245,244) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=244,245,244) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="9.8"/>
                    <measurement group_id="O3" value="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=244,245,244) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0"/>
                    <measurement group_id="O2" value="43.3"/>
                    <measurement group_id="O3" value="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=244,245,244) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.2"/>
                    <measurement group_id="O2" value="40.4"/>
                    <measurement group_id="O3" value="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3 (n=244,245,244) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=244,245,246) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4"/>
                    <measurement group_id="O2" value="3.7"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=244,245,246) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                    <measurement group_id="O2" value="22.9"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=244,245,246) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2"/>
                    <measurement group_id="O2" value="43.7"/>
                    <measurement group_id="O3" value="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=244,245,246) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3"/>
                    <measurement group_id="O2" value="26.5"/>
                    <measurement group_id="O3" value="58.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=244,245,246) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="3.3"/>
                    <measurement group_id="O3" value="32.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=244,245,246) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="20.4"/>
                    <measurement group_id="O3" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=244,245,246) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0"/>
                    <measurement group_id="O2" value="39.6"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=244,245,246) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9"/>
                    <measurement group_id="O2" value="29.0"/>
                    <measurement group_id="O3" value="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=244,245,246) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="10.2"/>
                    <measurement group_id="O3" value="53.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=244,245,246) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=244,245,246) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4"/>
                    <measurement group_id="O2" value="32.2"/>
                    <measurement group_id="O3" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=244,245,246) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.5"/>
                    <measurement group_id="O2" value="36.3"/>
                    <measurement group_id="O3" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=244,245,246) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="23.3"/>
                    <measurement group_id="O3" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=244,245,246) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.8"/>
                    <measurement group_id="O2" value="6.9"/>
                    <measurement group_id="O3" value="55.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=244,245,246) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants in Each IGA Mod 2011 Score Category Maintenance Period After Week 12 to Week 52</title>
        <description>The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.</description>
        <time_frame>Week 13,14,15,16,20,24,28,32,36,40,44,48,52</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
          <group group_id="O4">
            <title>AIN457 150mg From Placebo</title>
            <description>Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
          <group group_id="O5">
            <title>AIN457 300mg From Placebo</title>
            <description>Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants in Each IGA Mod 2011 Score Category Maintenance Period After Week 12 to Week 52</title>
          <description>The IGA mod 2011 scale is static, i.e. it referred exclusively to the participant's disease at the time of the assessment, and did not compare with any of the participant's previous disease states at previous visits. The scores are: 0 = clear, 1 = almost clear, 2 = mild, 3 = moderate, and 4 = severe.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="108"/>
                <count group_id="O5" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 13 (n=244,245,18,103,96) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6" spread="19.313"/>
                    <measurement group_id="O2" value="38.0" spread="15.935"/>
                    <measurement group_id="O3" value="11.1" spread="36.827"/>
                    <measurement group_id="O4" value="0.0" spread="28.240"/>
                    <measurement group_id="O5" value="0.0" spread="29.891"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=244,245,18,103,96) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" spread="18.832"/>
                    <measurement group_id="O2" value="35.9" spread="15.013"/>
                    <measurement group_id="O3" value="22.2" spread="30.225"/>
                    <measurement group_id="O4" value="1.0" spread="26.228"/>
                    <measurement group_id="O5" value="2.1" spread="28.809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=244,245,18,103,96) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0" spread="19.407"/>
                    <measurement group_id="O2" value="19.2" spread="14.769"/>
                    <measurement group_id="O3" value="27.8" spread="32.972"/>
                    <measurement group_id="O4" value="15.5" spread="23.561"/>
                    <measurement group_id="O5" value="14.6" spread="23.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=244,245,18,103,96) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="19.213"/>
                    <measurement group_id="O2" value="6.5" spread="15.367"/>
                    <measurement group_id="O3" value="27.8" spread="28.051"/>
                    <measurement group_id="O4" value="61.2" spread="23.591"/>
                    <measurement group_id="O5" value="59.4" spread="20.686"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13 (n=244,245,18,103,96) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="17.904"/>
                    <measurement group_id="O2" value="0.4" spread="16.263"/>
                    <measurement group_id="O3" value="11.1" spread="22.454"/>
                    <measurement group_id="O4" value="22.3" spread="20.587"/>
                    <measurement group_id="O5" value="24.0" spread="16.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=244,245,18,108,102) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.3" spread="20.240"/>
                    <measurement group_id="O2" value="41.6" spread="16.652"/>
                    <measurement group_id="O3" value="16.7" spread="25.062"/>
                    <measurement group_id="O4" value="0.0" spread="18.635"/>
                    <measurement group_id="O5" value="0.0" spread="13.969"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=244,245,18,108,102)almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" spread="20.417"/>
                    <measurement group_id="O2" value="36.7" spread="17.600"/>
                    <measurement group_id="O3" value="16.7" spread="23.943"/>
                    <measurement group_id="O4" value="4.6" spread="19.819"/>
                    <measurement group_id="O5" value="10.8" spread="11.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=244,245,18,108,102) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0" spread="21.887"/>
                    <measurement group_id="O2" value="13.5" spread="17.775"/>
                    <measurement group_id="O3" value="33.3" spread="25.879"/>
                    <measurement group_id="O4" value="30.6" spread="20.622"/>
                    <measurement group_id="O5" value="27.5" spread="13.240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=244,245,18,108,102)moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="25.048"/>
                    <measurement group_id="O2" value="7.3" spread="17.981"/>
                    <measurement group_id="O3" value="22.2" spread="24.608"/>
                    <measurement group_id="O4" value="56.5" spread="20.328"/>
                    <measurement group_id="O5" value="50.0" spread="16.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14 (n=244,245,18,108,102)severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="25.395"/>
                    <measurement group_id="O2" value="0.8" spread="17.385"/>
                    <measurement group_id="O3" value="11.1" spread="24.770"/>
                    <measurement group_id="O4" value="8.3" spread="20.762"/>
                    <measurement group_id="O5" value="11.8" spread="17.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=244,245,18,108,103) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1" spread="25.651"/>
                    <measurement group_id="O2" value="45.3" spread="17.804"/>
                    <measurement group_id="O3" value="11.1" spread="22.354"/>
                    <measurement group_id="O4" value="0.0" spread="18.277"/>
                    <measurement group_id="O5" value="1.9" spread="17.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=244,245,18,108,103) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.9" spread="26.471"/>
                    <measurement group_id="O2" value="33.9" spread="17.281"/>
                    <measurement group_id="O3" value="22.2" spread="21.506"/>
                    <measurement group_id="O4" value="13.9" spread="18.736"/>
                    <measurement group_id="O5" value="17.5" spread="18.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=244,245,18,108,103) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="26.524"/>
                    <measurement group_id="O2" value="14.7" spread="19.132"/>
                    <measurement group_id="O3" value="33.3" spread="22.169"/>
                    <measurement group_id="O4" value="38.9" spread="18.554"/>
                    <measurement group_id="O5" value="39.8" spread="20.615"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=244,245,18,108,103) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="42.6"/>
                    <measurement group_id="O5" value="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15 (n=244,245,18,108,103) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="4.6"/>
                    <measurement group_id="O5" value="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=244,245,18,108,103) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="47.3"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=244,245,18,108,103) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.7"/>
                    <measurement group_id="O2" value="30.6"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=244,245,18,108,103) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="15.9"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="7.4"/>
                    <measurement group_id="O5" value="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=244,245,18,108,103) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7"/>
                    <measurement group_id="O2" value="5.3"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="57.4"/>
                    <measurement group_id="O5" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16 (n=244,245,18,108,103) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="35.2"/>
                    <measurement group_id="O5" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=244,245,18,108,103) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.8"/>
                    <measurement group_id="O2" value="46.1"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=244,245,18,108,103) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.3"/>
                    <measurement group_id="O2" value="31.8"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="1.0"/>
                    <measurement group_id="O5" value="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=244,245,18,108,103) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="14.3"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="15.5"/>
                    <measurement group_id="O5" value="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=244,245,18,108,103) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5"/>
                    <measurement group_id="O2" value="7.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="61.2"/>
                    <measurement group_id="O5" value="10.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20 (n=244,245,18,108,103) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2"/>
                    <measurement group_id="O2" value="0.4"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="22.3"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=244,245,18,108,103) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="46.5"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=244,245,18,108,103) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7"/>
                    <measurement group_id="O2" value="29.0"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="4.6"/>
                    <measurement group_id="O5" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=244,245,18,108,103) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.6"/>
                    <measurement group_id="O2" value="15.1"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="30.6"/>
                    <measurement group_id="O5" value="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=244,245,18,108,103) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7"/>
                    <measurement group_id="O2" value="7.8"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="56.5"/>
                    <measurement group_id="O5" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (n=244,245,18,108,103) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="8.3"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=244,245,18,108,103) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6"/>
                    <measurement group_id="O2" value="46.5"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=244,245,18,108,103) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.8"/>
                    <measurement group_id="O2" value="26.5"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="13.9"/>
                    <measurement group_id="O5" value="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=244,245,18,108,103) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="38.9"/>
                    <measurement group_id="O5" value="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=244,245,18,108,103) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7"/>
                    <measurement group_id="O2" value="9.4"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="42.6"/>
                    <measurement group_id="O5" value="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28 (n=244,245,18,108,103) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="4.6"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=244,245,18,108,103) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                    <measurement group_id="O2" value="46.5"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="29.6"/>
                    <measurement group_id="O5" value="42.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=244,245,18,108,103) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.3"/>
                    <measurement group_id="O2" value="26.5"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="30.6"/>
                    <measurement group_id="O5" value="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=244,245,18,108,103) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="22.2"/>
                    <measurement group_id="O5" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=244,245,18,108,103) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3"/>
                    <measurement group_id="O2" value="9.0"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="14.8"/>
                    <measurement group_id="O5" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32 (n=244,245,18,108,103) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=244,245,18,108,103) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3"/>
                    <measurement group_id="O2" value="46.5"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="28.7"/>
                    <measurement group_id="O5" value="45.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=244,245,18,108,103) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="26.9"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=244,245,18,108,103) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4"/>
                    <measurement group_id="O2" value="16.7"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="18.5"/>
                    <measurement group_id="O5" value="16.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=244,245,18,108,103) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8"/>
                    <measurement group_id="O2" value="8.2"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="16.7"/>
                    <measurement group_id="O5" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (n=244,245,18,108,103) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=244,245,18,108,103) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.7"/>
                    <measurement group_id="O2" value="46.1"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="25.9"/>
                    <measurement group_id="O5" value="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=244,245,18,108,103) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="25.3"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="34.3"/>
                    <measurement group_id="O5" value="31.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=244,245,18,108,103) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="17.1"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="21.3"/>
                    <measurement group_id="O5" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=244,245,18,108,103) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="10.2"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="15.7"/>
                    <measurement group_id="O5" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40 (n=244,245,18,108,103) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=244,245,18,108,103) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5"/>
                    <measurement group_id="O2" value="42.9"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="25.9"/>
                    <measurement group_id="O5" value="40.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=244,245,18,108,103) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.0"/>
                    <measurement group_id="O2" value="24.1"/>
                    <measurement group_id="O3" value="38.9"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=244,245,18,108,103) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.4"/>
                    <measurement group_id="O2" value="20.4"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="20.4"/>
                    <measurement group_id="O5" value="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=244,245,18,108,103) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1"/>
                    <measurement group_id="O2" value="11.8"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="17.6"/>
                    <measurement group_id="O5" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44 (n=244,245,18,108,103) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                    <measurement group_id="O2" value="0.8"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=244,245,18,108,103) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.0"/>
                    <measurement group_id="O2" value="44.5"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="25.9"/>
                    <measurement group_id="O5" value="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=244,245,18,108,103) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1"/>
                    <measurement group_id="O2" value="25.3"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="28.7"/>
                    <measurement group_id="O5" value="34.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=244,245,18,108,103) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                    <measurement group_id="O2" value="16.3"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="27.8"/>
                    <measurement group_id="O5" value="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=244,245,18,108,103) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.1"/>
                    <measurement group_id="O2" value="12.7"/>
                    <measurement group_id="O3" value="16.7"/>
                    <measurement group_id="O4" value="14.8"/>
                    <measurement group_id="O5" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48 (n=244,245,18,108,103) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.9"/>
                    <measurement group_id="O2" value="1.2"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=244,245,18,108,103) clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.8"/>
                    <measurement group_id="O2" value="43.3"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="21.3"/>
                    <measurement group_id="O5" value="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=244,245,18,108,103) almost clear</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="24.1"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="31.5"/>
                    <measurement group_id="O5" value="29.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=244,245,18,108,103) mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1"/>
                    <measurement group_id="O2" value="19.6"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="28.7"/>
                    <measurement group_id="O5" value="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=244,245,18,108,103) moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0"/>
                    <measurement group_id="O2" value="11.4"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="15.7"/>
                    <measurement group_id="O5" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (n=244,245,18,108,103) severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9"/>
                    <measurement group_id="O2" value="1.6"/>
                    <measurement group_id="O3" value="5.6"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to PASI 75 Response up to 12 Weeks</title>
        <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (max). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 75 was defined as participants achieving ≥ 75% improvement from baseline.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to PASI 75 Response up to 12 Weeks</title>
          <description>PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk, legs; each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (max). Final PASI = sum of severity parameters for each area* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). PASI 75 was defined as participants achieving ≥ 75% improvement from baseline.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" lower_limit="55" upper_limit="85"/>
                    <measurement group_id="O2" value="57" lower_limit="29" upper_limit="59"/>
                    <measurement group_id="O3" value="NA">median could not be calculated because less than 50% of the participants achieved PASI 75</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) Health State Assessment (From 0 to 100) Induction Period</title>
        <description>The EQ-5D is an instrument used to assess a participant's health status. The instrument includes a descriptive profile and a visual analog scale (VAS). The descriptive profile includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 3 response levels: no problems, some problems and severe problems. The VAS is a vertical scale that assesses the health status from 0 (worst possible health state) to 100 (best possible health state). This outcome measures the percent change in VAS score. Positive mean percent changes indicate improvement.</description>
        <time_frame>Baseline, Week 4,8, 12</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) Health State Assessment (From 0 to 100) Induction Period</title>
          <description>The EQ-5D is an instrument used to assess a participant's health status. The instrument includes a descriptive profile and a visual analog scale (VAS). The descriptive profile includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 3 response levels: no problems, some problems and severe problems. The VAS is a vertical scale that assesses the health status from 0 (worst possible health state) to 100 (best possible health state). This outcome measures the percent change in VAS score. Positive mean percent changes indicate improvement.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>percent change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (238, 236,235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" spread="95.93" lower_limit="55" upper_limit="85"/>
                    <measurement group_id="O2" value="57.1" spread="234.10" lower_limit="29" upper_limit="59"/>
                    <measurement group_id="O3" value="6.3" spread="59.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (241, 242,241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.3" spread="142.28"/>
                    <measurement group_id="O2" value="72.7" spread="306.36"/>
                    <measurement group_id="O3" value="6.3" spread="65.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (242, 242,242)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" spread="158.66"/>
                    <measurement group_id="O2" value="76.3" spread="281.48"/>
                    <measurement group_id="O3" value="5.4" spread="67.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Percent Change From Baseline in EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) Health State Assessment (From 0 to 100) Maintenance Period</title>
        <description>The EQ-5D is an instrument used to assess a participant's health status. The instrument includes a descriptive profile and a visual analog scale (VAS). The descriptive profile includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 3 response levels: no problems, some problems and severe problems. The VAS is a vertical scale that assesses the health status from 0 (worst possible health state) to 100 (best possible health state). This outcome measures the percent change in VAS score. Positive mean percent changes indicate improvement.</description>
        <time_frame>Week 12, 24, 36, 52</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
          <group group_id="O4">
            <title>AIN457 150mg From Placebo</title>
            <description>Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
          <group group_id="O5">
            <title>AIN457 300mg From Placebo</title>
            <description>Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in EuroQOL 5-Dimension Health Status Questionnaire (EQ-5D) Health State Assessment (From 0 to 100) Maintenance Period</title>
          <description>The EQ-5D is an instrument used to assess a participant's health status. The instrument includes a descriptive profile and a visual analog scale (VAS). The descriptive profile includes 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension had 3 response levels: no problems, some problems and severe problems. The VAS is a vertical scale that assesses the health status from 0 (worst possible health state) to 100 (best possible health state). This outcome measures the percent change in VAS score. Positive mean percent changes indicate improvement.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percent Change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="108"/>
                <count group_id="O5" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (242, 242,18, 108, 104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.5" spread="158.66"/>
                    <measurement group_id="O2" value="76.3" spread="281.48"/>
                    <measurement group_id="O3" value="37.7" spread="83.41"/>
                    <measurement group_id="O4" value="-0.1" spread="38.95"/>
                    <measurement group_id="O5" value="3.3" spread="79.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (242, 242,18, 108, 97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.8" spread="140.46"/>
                    <measurement group_id="O2" value="78.0" spread="299.91"/>
                    <measurement group_id="O3" value="48.1" spread="92.06"/>
                    <measurement group_id="O4" value="28.1" spread="55.71"/>
                    <measurement group_id="O5" value="39.7" spread="80.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (242, 242,18, 108, 100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.1" spread="129.87"/>
                    <measurement group_id="O2" value="80.5" spread="300.89"/>
                    <measurement group_id="O3" value="45.3" spread="77.11"/>
                    <measurement group_id="O4" value="28.5" spread="60.39"/>
                    <measurement group_id="O5" value="43.8" spread="100.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (242, 242,18, 108,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.3" spread="128.86"/>
                    <measurement group_id="O2" value="76.9" spread="299.07"/>
                    <measurement group_id="O3" value="43.9" spread="81.50"/>
                    <measurement group_id="O4" value="28.3" spread="60.68"/>
                    <measurement group_id="O5" value="41.3" spread="95.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Changes in the Dermatology Life Quality Index (DLQI) During Induction Period</title>
        <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
        <time_frame>Baseline, Week 4, 8 &amp; 12</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Changes in the Dermatology Life Quality Index (DLQI) During Induction Period</title>
          <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (n=237,236,232)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-55.0" lower_limit="-58.9" upper_limit="-50.7"/>
                    <measurement group_id="O2" value="-62.5" lower_limit="-66.7" upper_limit="-58.6"/>
                    <measurement group_id="O3" value="-5.0" lower_limit="-10.1" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=241,242,239)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-73.1" lower_limit="-76.7" upper_limit="-69.2"/>
                    <measurement group_id="O2" value="-81.5" lower_limit="-84.4" upper_limit="-79.0"/>
                    <measurement group_id="O3" value="-8.3" lower_limit="-13.3" upper_limit="-2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=242,242,240)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.8" lower_limit="-81.3" upper_limit="-75.0"/>
                    <measurement group_id="O2" value="-86.4" lower_limit="-88.9" upper_limit="-83.3"/>
                    <measurement group_id="O3" value="-9.1" lower_limit="-15.6" upper_limit="-3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Changes in the Dermatology Life Quality Index (DLQI) During Maintenance Period</title>
        <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
        <time_frame>Week 12,24, 36 &amp; 52</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
          <group group_id="O4">
            <title>AIN457 150mg From Placebo</title>
            <description>Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
          <group group_id="O5">
            <title>AIN457 300mg From Placebo</title>
            <description>Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Changes in the Dermatology Life Quality Index (DLQI) During Maintenance Period</title>
          <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percent Change</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="108"/>
                <count group_id="O5" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (242,242,17,108,104)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-77.8" lower_limit="-81.3" upper_limit="-75.0"/>
                    <measurement group_id="O2" value="-86.4" lower_limit="-88.9" upper_limit="-83.3"/>
                    <measurement group_id="O3" value="-58.3" lower_limit="-80.0" upper_limit="-41.7"/>
                    <measurement group_id="O4" value="-7.1" lower_limit="-16.7" upper_limit="3.4"/>
                    <measurement group_id="O5" value="-4.4" lower_limit="-13.9" upper_limit="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (242,242,17,108,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-83.3" lower_limit="-87.5" upper_limit="-79.4"/>
                    <measurement group_id="O2" value="-89.6" lower_limit="-92.5" upper_limit="-86.0"/>
                    <measurement group_id="O3" value="-76.6" lower_limit="-88.9" upper_limit="-59.6"/>
                    <measurement group_id="O4" value="-83.3" lower_limit="-87.5" upper_limit="-76.7"/>
                    <measurement group_id="O5" value="-83.3" lower_limit="-89.9" upper_limit="-76.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (242,242,17,108,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-78.6" lower_limit="-83.3" upper_limit="-75.0"/>
                    <measurement group_id="O2" value="-91.7" lower_limit="-94.2" upper_limit="-88.9"/>
                    <measurement group_id="O3" value="-77.9" lower_limit="-93.3" upper_limit="-47.2"/>
                    <measurement group_id="O4" value="-78.5" lower_limit="-85.7" upper_limit="-66.7"/>
                    <measurement group_id="O5" value="-90.0" lower_limit="-93.3" upper_limit="-82.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (242,242,17,108,100)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-76.5" lower_limit="-80.6" upper_limit="-72.3"/>
                    <measurement group_id="O2" value="-88.9" lower_limit="-92.3" upper_limit="-85.7"/>
                    <measurement group_id="O3" value="-64.4" lower_limit="-83.3" upper_limit="-12.5"/>
                    <measurement group_id="O4" value="-75.0" lower_limit="-82.8" upper_limit="-66.2"/>
                    <measurement group_id="O5" value="-88.9" lower_limit="-92.9" upper_limit="-82.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) of 0 or 1 During Induction Period</title>
        <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
        <time_frame>Week 4, 8, 12</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) of 0 or 1 During Induction Period</title>
          <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4 (238, 237, 235)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.6"/>
                    <measurement group_id="O2" value="23.6"/>
                    <measurement group_id="O3" value="6.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (242,243,241)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.7"/>
                    <measurement group_id="O2" value="48.1"/>
                    <measurement group_id="O3" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (243,243,243)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1"/>
                    <measurement group_id="O2" value="58.8"/>
                    <measurement group_id="O3" value="10.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) of 0 or 1 During Maintenance Period</title>
        <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
        <time_frame>Week 12,24,36, &amp; 52</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
          <group group_id="O4">
            <title>AIN457 150mg From Placebo</title>
            <description>Patients randomized to AIN457 150mg in Maintenance phase when they were on Placebo in Induction Phase because they were PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
          <group group_id="O5">
            <title>AIN457 300mg From Placebo</title>
            <description>Patients randomized to AIN457 300mg in Maintenance phase when they were on Placebo in Induction Phase. PASI 75 non-responders and received their treatment on Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Achieved Dermatology Life Quality Index (DLQI) of 0 or 1 During Maintenance Period</title>
          <description>The DLQI is a ten item general dermatology disability index designed to assess health-related quality of life in adult participants with skin diseases such as eczema, psoriasis, acne and viral worts. It is a self-administered questionnaire which includes domains of daily activity, leisure, personal relationships, symptoms and feelings, treatment and school/work activities. Each domain has 4 response categories ranging from 0 (not at all) to 3 (very much). &quot;Not relevant&quot; is a valid score also and is scored as 0. The DLQI total score is a sum of all 10 responses. Scores range from 0 to 30 with higher scores indicating greater health-related quality of life impairment. A negative mean percentage change from baseline indicates improvement.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="18"/>
                <count group_id="O4" value="108"/>
                <count group_id="O5" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 12 (243,243,18,108,105)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1"/>
                    <measurement group_id="O2" value="58.8"/>
                    <measurement group_id="O3" value="27.8"/>
                    <measurement group_id="O4" value="10.2"/>
                    <measurement group_id="O5" value="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24 (243,243,18,108,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.7"/>
                    <measurement group_id="O2" value="64.6"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="53.7"/>
                    <measurement group_id="O5" value="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36 (243,243,18,108,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.9"/>
                    <measurement group_id="O2" value="68.7"/>
                    <measurement group_id="O3" value="50.0"/>
                    <measurement group_id="O4" value="56.5"/>
                    <measurement group_id="O5" value="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52 (243,243,18,108,101)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6"/>
                    <measurement group_id="O2" value="66.3"/>
                    <measurement group_id="O3" value="22.2"/>
                    <measurement group_id="O4" value="52.8"/>
                    <measurement group_id="O5" value="67.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving PASI 75, PASI 90 and IGA Mod 2011 0 or 1 Response at Week 12 by Previous Exposure to Biologic Systemic Therapy or Anti-TNF-α Therapy and Failed to Respond to a Previous Biologic or Anti-TNF-α Therapy Psoriasis Therapy</title>
        <description>PASI is an assessment of lesion severity &amp; affected area into a single score:0(no disease)to 72(max. disease).Body is divided into 4 areas for scoring(head,arms,trunk,legs)each area is scored separately &amp; then added for final PASI.For each area, % of skin involved is estimated:0(0%)to 6(90-100%)&amp; severity is estimated by clinical signs, erythema,induration &amp; desquamation;scale 0(none) to 4(max). Final PASI=sum of severity parameters for each area* area score weight of section(head:0.1,arms:0.2 body:0.3 legs:0.4).PASI 75, 90 is patients achieving≥75%or90% improvement from baseline.The IGA mod 2011 scale is static, exclusively to the patients disease at assessment,&amp; not with any of the patient's previous disease states at other visits.The scores are:0=clear,1=almost clear,2= mild,3=moderate&amp;4=severe.Response variables PASI 75,90, IGA mod 2011 0 or 1 response at wk 12 was scored versus previous psoriasis systemic therapy &amp; response to previous biologic systemic therapy by treatment</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving PASI 75, PASI 90 and IGA Mod 2011 0 or 1 Response at Week 12 by Previous Exposure to Biologic Systemic Therapy or Anti-TNF-α Therapy and Failed to Respond to a Previous Biologic or Anti-TNF-α Therapy Psoriasis Therapy</title>
          <description>PASI is an assessment of lesion severity &amp; affected area into a single score:0(no disease)to 72(max. disease).Body is divided into 4 areas for scoring(head,arms,trunk,legs)each area is scored separately &amp; then added for final PASI.For each area, % of skin involved is estimated:0(0%)to 6(90-100%)&amp; severity is estimated by clinical signs, erythema,induration &amp; desquamation;scale 0(none) to 4(max). Final PASI=sum of severity parameters for each area* area score weight of section(head:0.1,arms:0.2 body:0.3 legs:0.4).PASI 75, 90 is patients achieving≥75%or90% improvement from baseline.The IGA mod 2011 scale is static, exclusively to the patients disease at assessment,&amp; not with any of the patient's previous disease states at other visits.The scores are:0=clear,1=almost clear,2= mild,3=moderate&amp;4=severe.Response variables PASI 75,90, IGA mod 2011 0 or 1 response at wk 12 was scored versus previous psoriasis systemic therapy &amp; response to previous biologic systemic therapy by treatment</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IGA 0/1 biologic (29, 19, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.4"/>
                    <measurement group_id="O2" value="57.9"/>
                    <measurement group_id="O3" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 biologic (29, 19, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3"/>
                    <measurement group_id="O2" value="57.9"/>
                    <measurement group_id="O3" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 biologic (29, 19, 24)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                    <measurement group_id="O2" value="31.6"/>
                    <measurement group_id="O3" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IGA 0/1 anti-TNF-α therapy (18,17,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="64.7"/>
                    <measurement group_id="O3" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 75 anti-TNF-α therapy (18,17,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6"/>
                    <measurement group_id="O2" value="64.7"/>
                    <measurement group_id="O3" value="14.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PASI 90 anti-TNF-α therapy (18,17,21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="35.3"/>
                    <measurement group_id="O3" value="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Developed Anti-secukinumab Antibodies</title>
        <description>The development of anti-secunimubab anti-bodies would decrease a participant’s ability to respond to secukinumab treatment.</description>
        <time_frame>Week 12</time_frame>
        <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>AIN457 150 mg</title>
            <description>AIN457 secukinumab 150 mg subcutaneous (s.c.) injection plus a placebo secukinumab s.c. injection once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4 and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O2">
            <title>AIN457 300 mg</title>
            <description>AIN457 secukinumab 300 mg (two s.c. injections of 150 mg) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks, starting at Week 4, and until Week 48, except for Weeks 13, 14, and 15 when they received two s.c. injections of placebo per week</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>placebo secukinumab (two s.c. injections per dose) once weekly for 4 weeks (at randomization, Weeks 1, 2, and 3), followed by dosing every 4 weeks (Weeks 4 and 8). Prior to receiving the Week 12 dose, all patients in the placebo group were assigned to the following treatment groups based on their PASI 75 response at Week 12. PASI 75 responders: continued on placebo and received their placebo injections at Weeks 12, 13, 14, 15, and then every 4 weeks starting at Week 16 until Week 48.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Developed Anti-secukinumab Antibodies</title>
          <description>The development of anti-secunimubab anti-bodies would decrease a participant’s ability to respond to secukinumab treatment.</description>
          <population>Full analysis set (FAS): The FAS was comprised of all patients to whom study treatment had been assigned. Following the intent-to-treat principle, patients were analyzed according to the treatment assigned to at randomization. If the actual stratum was different to the assigned stratum in IRT, the actual stratum was used in analyses.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="245"/>
                <count group_id="O2" value="245"/>
                <count group_id="O3" value="247"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>INDUCTION-AIN457 150mg</title>
          <description>INDUCTION-AIN457 150mg</description>
        </group>
        <group group_id="E2">
          <title>INDUCTION-AIN457 300mg</title>
          <description>INDUCTION-AIN457 300mg</description>
        </group>
        <group group_id="E3">
          <title>INDUCTION-Placebo</title>
          <description>INDUCTION-Placebo</description>
        </group>
        <group group_id="E4">
          <title>ENTIRE-AIN457 150mg</title>
          <description>ENTIRE-AIN457 150mg</description>
        </group>
        <group group_id="E5">
          <title>ENTIRE-AIN457 300mg</title>
          <description>ENTIRE-AIN457 300mg</description>
        </group>
        <group group_id="E6">
          <title>ENTIRE-Any AIN457 150mg</title>
          <description>ENTIRE-Any AIN457 150mg</description>
        </group>
        <group group_id="E7">
          <title>ENTIRE-Any AIN457 300mg</title>
          <description>ENTIRE-Any AIN457 300mg</description>
        </group>
        <group group_id="E8">
          <title>ENTIRE-Placebo</title>
          <description>ENTIRE-Placebo</description>
        </group>
        <group group_id="E9">
          <title>FOLLOW UP-Any AIN457 150mg</title>
          <description>FOLLOW UP-Any AIN457 150mg</description>
        </group>
        <group group_id="E10">
          <title>FOLLOW UP-Any AIN457 300mg</title>
          <description>FOLLOW UP-Any AIN457 300mg</description>
        </group>
        <group group_id="E11">
          <title>FOLLOW UP-Placebo</title>
          <description>FOLLOW UP-Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMORRHAGIC ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>SUDDEN HEARING LOSS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL HERNIA OBSTRUCTIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>COLITIS ULCERATIVE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>COMMINUTED FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>CONCUSSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>LARYNGEAL INJURY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>MULTIPLE INJURIES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PELVIC FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PULMONARY CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>RADIUS FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>RIB FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>TOXICITY TO VARIOUS AGENTS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>HYPOPROTEINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>TYPE 2 DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BURSITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BASAL CELL CARCINOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>BENIGN NEOPLASM OF SKIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>BLADDER CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>FOLLICULAR THYROID CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>THYROID CANCER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>UTERINE LEIOMYOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CAROTID ARTERY DISSECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC STROKE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>HALLUCINATION, AUDITORY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PANIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>OBSTRUCTIVE UROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PULMONARY MASS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>ABORTION INDUCED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AORTIC ANEURYSM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>AORTIC THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>HYPERTENSIVE CRISIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="108" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="102" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="172" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="161" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="228" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="229" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="85" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>TOOTHACHE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="17" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>FURUNCLE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="53" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="45" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="69" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="57" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="20" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PERIODONTITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>RHINITIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>TINEA PEDIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="28" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="36" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="32" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>VIRAL UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>VULVOVAGINAL MYCOTIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>CONTUSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>EXCORIATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>LIGAMENT SPRAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>MUSCLE STRAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERLIPIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>HYPERTRIGLYCERIDAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="14" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC PROTRUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PSORIATIC ARTHROPATHY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="24" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="30" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DERMATITIS CONTACT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>ECZEMA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>PSORIASIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="245"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="245"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="245"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="245"/>
                <counts group_id="E6" subjects_affected="21" subjects_at_risk="353"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="349"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="247"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="58"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="47"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

